实验性化合物TOFA在小鼠实验中显示燃脂同时保留肌肉的潜力

加州大学伯克利分校研究人员发现了一种名为TOFA的实验性化合物，能够通过提高能量消耗而非抑制食欲的方式帮助燃烧脂肪。1在小鼠实验中，TOFA使能量消耗增加高达18%，同时减少身体脂肪且无显著肌肉损失。1这一化合物还改善了受试小鼠的血糖水平、甘油三酯和脂肪肝疾病等指标。1

TOFA是一种ACC抑制剂，同时激活PPARα和PPARδ受体。1该化合物与GLP-1类药物（包括Ozempic、Wegovy、Mounjaro和Zepbound等）联合使用时，产生了更强的改善效果。1

研究人员强调，TOFA迄今仅在动物模型中进行了研究，其在人类中的安全性和有效性仍需进一步评估。1该研究成果已发表于2026年8月21日的《Science Advances》杂志。1

Researchers at the University of California, Berkeley have identified an experimental compound called TOFA that promotes fat burning by increasing energy expenditure rather than suppressing appetite.1 In mouse studies, TOFA boosted energy consumption by up to 18% while reducing body fat without significant muscle loss, and also improved blood glucose levels, triglycerides, and fatty liver disease.1 The compound demonstrated even greater benefits when combined with GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound.1

TOFA functions as an ACC inhibitor while simultaneously activating PPARα and PPARδ receptors.1 The findings were published on August 21, 2026, in the journal Science Advances.1 Researchers emphasized that TOFA has so far been studied only in animals, and its safety and efficacy in humans remain to be evaluated.1